These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34350670)

  • 1. Scutellarein induces apoptosis and inhibits proliferation, migration, and invasion in ovarian cancer via inhibition of EZH2/FOXO1 signaling.
    Lang X; Chen Z; Yang X; Yan Q; Xu M; Liu W; He Q; Zhang Y; Cheng W; Zhao W
    J Biochem Mol Toxicol; 2021 Oct; 35(10):e22870. PubMed ID: 34350670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
    Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
    Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scutellarein inhibits cancer cell metastasis in vitro and attenuates the development of fibrosarcoma in vivo.
    Shi X; Chen G; Liu X; Qiu Y; Yang S; Zhang Y; Fang X; Zhang C; Liu X
    Int J Mol Med; 2015 Jan; 35(1):31-8. PubMed ID: 25394920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of EZH2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
    Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
    Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells.
    Zheng M; Cao MX; Luo XJ; Li L; Wang K; Wang SS; Wang HF; Tang YJ; Tang YL; Liang XH
    J Cell Mol Med; 2019 Oct; 23(10):6942-6954. PubMed ID: 31368152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
    Yuan S; Xu Y; Yi T; Wang H
    J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription.
    Zhang KJ; Tan XL; Guo L
    Mol Oncol; 2020 Feb; 14(2):309-328. PubMed ID: 31860165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 9. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
    Zhang N; Qiu J; Zheng T; Zhang X; Hua K; Zhang Y
    Oncol Rep; 2018 Mar; 39(3):1034-1042. PubMed ID: 29286125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
    Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
    Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
    [No Abstract]   [Full Text] [Related]  

  • 11.
    Guo J; Zhu H; Li Q; Dong J; Xiong W; Yu K
    Aging (Albany NY); 2021 Apr; 13(8):11665-11677. PubMed ID: 33879635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.
    Yang X; Wang J; Li H; Sun Y; Tong X
    Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
    Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
    J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
    [TBL] [Abstract][Full Text] [Related]  

  • 15.  Effect of siRNA targeting EZH2 on cell viability and apoptosis of bladder cancer T24 cells.
    Wang HF; Yang H; Hu LB; Lei YH; Qin Y; Li J; Bi CW; Wang JS; Huo Q
    Genet Mol Res; 2014 Nov; 13(4):9939-50. PubMed ID: 25501205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to EZH2.
    Chen XJ; An N
    J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropivacaine suppresses the progression of renal cell carcinoma through regulating the lncRNA RMRP/EZH2/CCDC65 axis.
    Xiong Y; Zheng X; Deng H
    Daru; 2024 Jun; 32(1):121-132. PubMed ID: 38008820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of EZH2 via activation of SAPK/JNK and reduction of p65 and DNMT1 as a novel mechanism in inhibition of human lung cancer cells by polyphyllin I.
    Li L; Wu J; Zheng F; Tang Q; Wu W; Hann SS
    J Exp Clin Cancer Res; 2016 Jul; 35(1):112. PubMed ID: 27421653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
    Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
    J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
    Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.